Telmisartan-based monotherapy and combination regimens for blood pressure control in adults with hypertension: a systematic review, meta-analysis, and GRADE assessment

Baraah Abu Alsel, Muzun Saleh Alturqi Alanazi, Aryam Salem Mgairan Alrawaili, Shahad Ayed Alenezi, Safya E Esmaeel, Manal S Fawzy, Yehia Nabil · 2026

Read Telmisartan-based monotherapy and combination regimens for blood pressure control in adults with hypertension: a systematic review, meta-analysis, and GRADE assessment by Baraah Abu Alsel, Muzun Saleh Alturqi Alanazi, Aryam Salem Mgairan Alrawaili, Shahad Ayed Alenezi, Safya E Esmaeel, Manal S Fawzy, Yehia Nabil (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13540821.txt.

Description

Baraah Abu Alsel and six co-authors pooled the evidence on a blood pressure drug in a 2026 review. Telmisartan is widely used for hypertension, alone and in combination pills. The team gathered trials comparing telmisartan-based plans with placebo, usual care, or other drugs.

Twenty-four trials with 6,521 patients met their rules. Telmisartan-based therapy lowered office systolic pressure by about six points and diastolic by about five against the mixed comparators. The size of the benefit depended on what it was compared with, and the certainty of evidence was rated low. Side effects and safety were weighed alongside. The authors present the pooled numbers as a guide, not a verdict, for prescribers.

Catalog record

CREATORBaraah Abu Alsel, Muzun Saleh Alturqi Alanazi, Aryam Salem Mgairan Alrawaili, Shahad Ayed Alenezi, Safya E Esmaeel, Manal S Fawzy, Yehia Nabil
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE68 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13540821

Browse the full library · About the Tower of Babel